- Home
- MSD vs SCPH Comparison
MSD vs SCPH Comparison
Compare MSD & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- SCPH
- Stock Information
- Founded
- MSD 1993
- SCPH 2013
- Country
- MSD United States
- SCPH United States
- Employees
- MSD N/A
- SCPH N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MSD Finance
- SCPH Health Care
- Exchange
- MSD Nasdaq
- SCPH Nasdaq
- Market Cap
- MSD 162.9M
- SCPH 173.6M
- IPO Year
- MSD N/A
- SCPH 2017
- Fundamental
- Price
- MSD $8.10
- SCPH $2.78
- Analyst Decision
- MSD
- SCPH Strong Buy
- Analyst Count
- MSD 0
- SCPH 3
- Target Price
- MSD N/A
- SCPH $14.00
- AVG Volume (30 Days)
- MSD 70.2K
- SCPH 629.3K
- Earning Date
- MSD 01-01-0001
- SCPH 03-19-2025
- Dividend Yield
- MSD 11.26%
- SCPH N/A
- EPS Growth
- MSD N/A
- SCPH N/A
- EPS
- MSD N/A
- SCPH N/A
- Revenue
- MSD N/A
- SCPH $36,332,000.00
- Revenue This Year
- MSD N/A
- SCPH $134.20
- Revenue Next Year
- MSD N/A
- SCPH $99.40
- P/E Ratio
- MSD N/A
- SCPH N/A
- Revenue Growth
- MSD N/A
- SCPH 167.28
- 52 Week Low
- MSD $6.11
- SCPH $2.72
- 52 Week High
- MSD $7.46
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- MSD 45.31
- SCPH 34.45
- Support Level
- MSD $8.01
- SCPH $2.87
- Resistance Level
- MSD $8.32
- SCPH $3.08
- Average True Range (ATR)
- MSD 0.10
- SCPH 0.18
- MACD
- MSD -0.01
- SCPH -0.00
- Stochastic Oscillator
- MSD 29.03
- SCPH 11.70
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.